FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for treating a disease, associated with target cells, expressing CD138. For this purpose to a patient in need introduced is an effective quality of an immunoconjugate, which contains at least one targeting antibody, for which CD138-expressing cells represent the target, and at least one effector molecule, where the said targeting antibody if functionally bound with the said effector molecule with the formation of the said immunoconjugate, where at least one targeting antibody contains a heavy chain, which is identical to sequence SEQ ID NO: 1, by at least 70%, and a light chain, which is identical to sequence SEQ ID NO: 2 by at least 70%, and where the said patient has a resistance phenotype. The group of inventions also relates to an anticancer combination and an anticancer set, containing the said immunoconjugate.
EFFECT: application of the immunoconjugate in a combination with a cyctotoxic preparation results in a synergic anticancer effect.
61 cl, 3 ex, 30 dwg, 19 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| CD138-TARGETED CELL AGENTS AND USING THEM | 2008 |
|
RU2537265C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF | 2010 |
|
RU2587621C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | 2014 |
|
RU2696579C2 |
| ANTIBODIES TO FcRH5, THEIR IMMUNOCONJUGATES AND METHODS OF THEIR USE | 2010 |
|
RU2583270C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
